Funding

Current

1R01EY032461-01, NEI , National Institute of Health/NEI (6/2021-5/2026)
Claudio Punzo, Ph.D., (Role: Co-PI)
Title: Identifying the cause for photoreceptor-mediated retinal-pigmented epithelium atrophy.
Total direct cost: $ 1,250,000 

Research to Prevent Blindness/American Macular Degeneration Catalyst Award (1/2023-12/2025)
Claudio Punzo (Role: PI)
Title:   Development of Stable siRNA therapeutics for the treatment of neovascular AMD  
Total direct cost: $ 160,000

Kang Hong Pharmaceutical, (2/2018-1/2024)
Guangping Gao, Ph.D., (Role: Co-PI)
Title: AAV vector based in vivo delivery of therapeutic genes to retina for the treatment of ophthalmic disorders.
Total direct cost: $ ~595,000

Completed

BrightFocus Foundation for Macular Degeneration (9/2020-8-2022)
Claudio Punzo (Role: PI)
Title: Elucidating how smoking contributes to AMD
Total direct cost: $ 185,000

R21 EY030166-01, National Institute of Health/NEI (2/2020-1/2022)
Frances Lefcort, Ph.D., (Role: Co-PI)
Title: Therapeutic strategies for mitigating loss of retinal ganglion cells in familial dysautonomia.
Total direct cost: $ ~40,000

R21 EY030166-01, National Institute of Health/NEI (4/2019-3/2021)
Claudio Punzo, Ph.D., (Role: PI)
Title: Testting the role of Glucose deprivation during secondary cone death in retinitis pigmentosa.
Total direct cost: $ 275,000

1R01EY023570-06, National Institute of Health/NEI (8/2013-7/2019)
Claudio Punzo, Ph.D., (Role: PI)
Title: Delaying Cone Death in Retinitis Pigmentosa
Total direct cost: $ 1,250,000

BrightFocus Foundation for Macular Degeneration (7/2017-6-2019)
Claudio Punzo (Role: PI)
Title: Role of photoreceptors in age-related macular degeneration
Total direct cost: $ 160,000 

Massachusetts Lions Eye Research Fund Inc., (9/2015-8/2016)
Claudio Punzo, Ph.D., (Role: PI)
Title: Prolonging vision in Age-related Macular degeneration
Total direct cost: $ 15,333 

International Retinal Research Foundation (IRRF) (10/2013-9/2015)
Claudio Punzo Ph.D, (Role: PI)
Title: Modulation of the mTOR pathway: A novel approach to extend vision in dry Age-related macular degeneration.
Total direct cost: $ 200,000